Tag: metastatic

>>
★ Trastuzumab deruxtecan demonstrates a median progression-free survival of 13.2 months versus 8.1 with chemotherapy in HER2-low and HER2-ultralow hormone-positive metastatic breast cancer after one or more lines of endocrine therapy

Read More

June 10, 2024June 10, 2024 adminadmin

★ Trastuzumab deruxtecan demonstrates a median progression-free survival of 13.2 months versus 8.1 with chemotherapy in HER2-low and HER2-ultralow hormone-positive metastatic breast cancer after one or more lines of endocrine therapy

Positive results from the phase 3 DESTINY-Breast06 trial showed that trastuzumab deruxtecan demonstrated a statistically…
0 Comments
Survival as hope, not as a possibility: “I am one of those people who has exceeded the average of five years of life with metastatic breast cancer”

Read More

June 9, 2024June 9, 2024 adminadmin

Survival as hope, not as a possibility: “I am one of those people who has exceeded the average of five years of life with metastatic breast cancer”

Dr. Soraya Casla teaches oncological exercise workshops. (Dare)“Why did this happen to me?” he asked…
0 Comments